KR940006590A - 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물 - Google Patents

알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물 Download PDF

Info

Publication number
KR940006590A
KR940006590A KR1019930018138A KR930018138A KR940006590A KR 940006590 A KR940006590 A KR 940006590A KR 1019930018138 A KR1019930018138 A KR 1019930018138A KR 930018138 A KR930018138 A KR 930018138A KR 940006590 A KR940006590 A KR 940006590A
Authority
KR
South Korea
Prior art keywords
alkyl
hydrogen
phenyl
substituted
alkylthio
Prior art date
Application number
KR1019930018138A
Other languages
English (en)
Inventor
모우디 부에-발레스케이 줄리아나
챨스 훈덴 데이비드
데이비드 존스 챨스
앤 패네타 질
노만 쇼우 월터
Original Assignee
리로이 휘테커
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리로이 휘테커, 일라이 릴리 앤드 캄파니 filed Critical 리로이 휘테커
Publication of KR940006590A publication Critical patent/KR940006590A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65H—HANDLING THIN OR FILAMENTARY MATERIAL, e.g. SHEETS, WEBS, CABLES
    • B65H2511/00—Dimensions; Position; Numbers; Identification; Occurrences
    • B65H2511/50—Occurence
    • B65H2511/51—Presence
    • B65H2511/512—Marks, e.g. invisible to the human eye; Patterns

Abstract

특정 로다닌 유도체를 이용한 과혈당증 및 알쯔하이머 질환의 치료방법이 제공된다. 본 치료 방법에 사용되는 로다닌 유도체는 신규화합물이며, 이 화합물 그의 제조방법 및 그의 약학적 제제도 제공된다.

Description

알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 포유 동물의 혈중 글루코스 농도를 감소시키기에 유용한 약제의 제조를 위한 하기 일반식(Ⅰ)의 화합물 또는 그의 약학적으로 허용가능한 염의 용도:
    상기식에서, Ar은 (ⅰ)페닐, (ⅱ)C1-C8알킬,C1-C8알콕시, C1-C8알킬티오, 트리플루오로메틸, C1-C4알킬페닐, 페닐, NO2,F,CL, 하이드록시, 페녹시, C1-C4알킬옥시페닐, 티오페닐, C1-C4알킬티오페닐, COOR7,-N(R7)2또는 -N(R7)SO2R7(여기서, 각 R7은 독립적으로 수소 또는 C1-C6알킬이다)중에서 독립적으로 선택된 1내지 3의 치환체로 치환된 페닐, (iii)1-또는 2-나프틸, (iv)2-또는3-벤조푸라닐, (v)2-또는3-벤조티오페닐, (vi)2-또는3-티에닐, (vii)2-,3-또는 4-피리딜, (viii)2-또는3-푸라닐, (ix)1,3-벤조디옥사닐, (x)치환된1,3-벤조디옥사닐, (xi)퀴놀리닐, (xii)2-또는3-인돌릴 또는 (xiii)N-치환된 2-또는 3-인돌릴이고, R1은 C1-C6알킬, C1-C4알킬페닐, 수소, 페닐, 또는 Cl,Br,F,l, C1-C4알킬, C1-C4알콕시, 하이드록시, 트리플루오로메틸, -NH2, -NH(C1-C4알킬), -N(C1-C4알킬)2또는 C1-C4알킬티오중에서 독립적으로 선택된 1 또는 2의 치환체로 치환된 페닐이고, R2및 R3는 각각 수소이고 또는 함께 취해질 경우 결합을 형성하고, R4및 R5는 각각 수소이고 또는 함께 취해질 경우 =S이고, 또는 R4와 R5중의 하나가 수소일 경우 다른 하나는 -SCH3이고,R6은 수소, C1-C6알킬, C3-C8시클로알킬, C2-C6알케닐, -SO2CH3또는 -(CH2)p-Y[여기서, p는 0,1,2또는 3이고 Y는 시아노, -OR8,테트라졸릴, -NR10R11, -SH, C1-C4알킬티오 또는--O-C1-C4알킬(여기서, R8은 수소, C1-C4알킬 또는알킬이고, R9는 수소, C1-C4알킬, C1-C4알콕시, 하이드록시 또는 NH2이고, R10및 R11은 각각 독립적으로 수소, C1-C6알킬, C2-C6알케닐, C2-C6알키닐, 페닐, C1-C4알킬페닐, -(CH2)qN(C1-C4알킬)2또는 -(CH2)qS(C1-C4알킬)(여기서, q는 1내지 6이다)이고 또는 R10과 R11은 이들이 결합하는 질소원자와 함께 취해져 모르폴리닐, 피페리디닐, 피페라지닐 또는 N-메틸피페라지닐 고리를 형성한다)이다]이고, m은 0,1 또는 2이고, 단, Ar은 페닐 고리의 4-위치에 하나의 클로로 치환체만으로 치환된 페닐일수 없고,Ar은 페닐 고리의 2-위치에 COOH잔기로 치환된 페닐일 수 없고, Ar이 페닐 고리의 3- 및 4-위치에 2개의 에톡시 잔기로 치환된 페닐일 경우, R1은 수소이어야하고, Ar은 두개의 하이드록시 치환체만으로 치환된 페닐일 수 없고, R4와 R5가 각각 수소일 경우, R6은 C1-C6알킬일 수 없다.
  2. 제1항에 있어서, 사용된 화합물이 5-[(3-메톡시-4-펜톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논 또는 그의 약학적으로 허용가능한 염인 용도.
  3. 하나 또는 그 이상의 약학적으로 허용가능한 담체, 희석제 또는 부형제와 함께 혼합된 제1항 또는 제2항에 기재된 화합물을 포함하는, 혈중 글루코스 농도를 감소시키기 위한 약학적 제제.
  4. 알쯔하이머 질환의 치료에 유용한 약제의 제조를 위한 하기 일반식(I)의 화합물 또는 그의 약학적으로 허용가능한 염의 농도:
    상기식에서, Ar은 (i)페닐, (ii)C1-C8알킬, C1-C8알콕시, C1-C8알킬티오, 트리플루오로메틸, C1-C4알킬티오페닐, 페닐, NO2,F,Cl, 하이드록시, 페녹시, C1-C4알킬옥시페닐, 티오페닐, C1-C4알킬티오페닐, -COOR7, -N(R7)2또는 -N(R7)SO2R7(여기서, 각 R7은 독립적으로 수소 또는 C1-C6알킬이다)중에서 독립적으로 선택된 1내지 3의 치환체로 치환된 페닐, 또는 (iii)1- 또는 2-나프틸이고, R1은 C1-C6알킬, C1-C4알킬페닐, 수소, 페닐, 또는 Cl,Br,F,l, C1-C4알킬, C1-C4알콕시, 하이드록시, 트리플루오로메틸, -NH2, -NH(C1-C4알킬), -N(C1-C4알킬)2또는 C1-C4알킬티오중에서 독립적으로 선택된 1 또는 2의 치환체로 치환된 페닐이고, R2및 R3는 각각 수소이고 또는 함께 취해질 경우 결합을 형성하고, R4및 R5는 각각 수소이고 또는 함께 취해질 경우 =S이고, 또는 R4와 R5중의 하나가 수소일 경우 다른 하나는 -SCH3이고,R6은 수소, C1-C6알킬, C3-C8시클로알킬, C2-C6알케닐, -SO2CH3또는 -(CH2)p-Y[여기서, p는 0,1,2또는 3이고 Y는 시아노, -OR8,테트라졸릴, -NR10R11, -SH, C1-C4알킬티오 또는--O-C1-C4알킬(여기서, R8은 수소, C1-C4알킬 또는알킬이고, R9는 수소, C1-C4알킬, C1-C4알콕시, 하이드록시 또는 NH2이고, R10및 R11은 각각 독립적으로 수소, C1-C6알킬, C2-C6알케닐, C2-C6알키닐, 페닐, C1-C4알킬페닐, -(CH2)qN(C1-C4알킬)2또는 -(CH2)qS(C1-C4알킬)(여기서, q는 1내지 6이다)이고 또는 R10과 R11은 이들이 결합하는 질소원자와 함께 취해져 모르폴리닐, 피페리디닐, 피페라지닐 또는 N-메틸피페라지닐 고리를 형성한다)이다]이고, m은 0,1 또는 2이다.
  5. 제4항에 있어서, 사용된 화합물이 5-[(3-(1,1-디메틸에틸)-4-하이드록시-5(메틸티오페닐)페닐]메티렌]-2-티옥소-4-티아졸리디논 또는 그의 약학적으로 허용가능한 염인 용도.
  6. 하나 또는 그 이상의 약학적으로 허용가능한 담체, 희석제 또는 부형제와 함께 혼합된 제5항 또는 제6항에 기재된 화합물을 포함하는, 알쯔하이머 질환의 치료를 위한 약학적 제제.
  7. 하기 일반식(Ⅰ)의 화합물 또는 그의 약학적으로 허용가능한 염:
    상기식에서, Ar은 (i)페닐, (ii)C1-C8알킬, C1-C8알콕시, C1-C8알킬티오, 트리플루오로메틸, NO2, F, Cl, 페녹시, C1페닐, 티오페닐, C1-C4알킬티오페닐, -COOR7, -N(R7)2또는 -N(R7)SO2R7(여기서, 각 R7은 독립적으로 수소 또는 함께 취해질 경우 결합을 형성하고, R4및 R5는 각각 수소이고 또는 C1-C6알킬이다)중에서 독립적으로 선택된 1 내지 3의 치환체로 치환된 페닐, 또는 (iii)1-또는 2-나프틸, (iv)2-또는3-벤조푸라닐, (v)2-또는3-벤조티오페닐, (vi)2-또는3-티에닐, (vii)2-,3-또는 4-피리딜, (viii)2-또는3-푸라닐, (ix)1,3-벤조디옥사닐, (x)치환된1,3-벤조디옥사닐, (xi)퀴놀리닐, (xii)2-또는3-인돌릴 또는 (xiii)N-치환된 2-또는 3-인돌릴이고, R1은 C1-C6알킬, C1-C4알킬페닐, 수소, 페닐, 또는 Cl,Br,F,l, C1-C4알킬, C1-C4알콕시, 하이드록시, 트리플루오로메틸, -NH2, -NH(C1-C4알킬), -N(C1-C4알킬)2또는 C1-C4알킬티오중에서 독립적으로 선택된 1 또는 2의 치환체로 치환된 페닐이고, R2및 R3는 각각 수소이고 또는 함께 취해질 경우 결합을 형성하고, R4및 R5는 각각 수소이고 또는 함께 취해질 경우 =S이고, 또는 R4와 R5중의 하나가 수소일 경우 다른 하나는 -SCH3이고,R6은 수소, C1-C6알킬, C3-C8시클로알킬, C2-C6알케닐, -SO2CH3또는 -(CH2)p-Y[여기서, p는 0,1,2또는 3이고 Y는 시아노, -OR8,테트라졸릴, -NR10R11, -SH, C1-C4알킬티오 또는--O-C1-C4알킬(여기서, R8은 수소, C1-C4알킬 또는알킬이고, R9는 수소, C1-C4알킬, C1-C4알콕시, 하이드록시 또는 NH2이고, R10및 R11은 각각 독립적으로 수소, C1-C6알킬, C2-C6알케닐, C2-C6알키닐, 페닐, C1-C4알킬페닐, -(CH2)qN(C1-C4알킬)2또는 -(CH2)qS(C1-C4알킬)(여기서, q는 1내지 6이다)이고 또는 R10과 R11은 이들이 결합하는 질소원자와 함께 취해져 모르폴리닐, 피페리디닐, 피페라지닐 또는 N-메틸피페라지닐 고리를 형성한다)이다]이고, m은 0,1 또는 2이고, (ⅰ)페닐, (ⅱ)C1-C8알킬,C1-C8알콕시, F,Cl, 트리플루오로메틸, 페녹시, C1-C4알킬옥시페닐, C1-C8알킬티오, NO2,-N(R7)2또는 -COOR7(여기서, 각 R7은 독립적으로 수소 또는 C1-C6알킬이다)중에서 독립적으로 선택된 1내지 3의 치환체로 치환된 페닐, (iii)1-또는 2-나프틸, (iv)2-또는3-벤조푸라닐, (v)2-또는3-벤조티오페닐, (vi)2-또는3-티에닐, (vii)2-또는 3-인돌릴, (viii)2-또는3-푸라닐, (ix)2-,3-또는 4-피리딜 또는 (x)퀴놀리닐이고, R1이 수소 또는 C1-C6알킬이고, R2및 R3가 함께 결합을 형성하고, m이 0이고, R4및 R5는 함께 취해져 =S일 경우, R6은 수소 또는 C1-C6알킬이 아닌 다른 것이여야 하고, Ar이 페닐 고리의 4-위치에 하나의 클로로 치환체만으로 치환된 페닐일수 없고, Ar이 페닐 고리의 3- 및 4-위치에 2개의 에톡시 잔기로 치환된 페닐일 경우, R1은 수소이어야 하고, Ar이 페닐고리의 2-위치에 COOH잔기로 치환된 페닐일 수 없고, R4및 R5가 각각 수소일 경우, R6은 C1-C6알킬일 수 없다.
  8. 화합물 5-[(3-메톡시-4-펜톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논 또는 그의 약학적으로 허용가능한 염.
  9. 화합물 5-[(3-(1,1-디메틸에틸)-4-하이드록시75(메틸티오페닐)페닐]메티렌]-2-티옥소-4-티아졸리디논 또는 그의 약학적으로 허용가능한 염.
  10. 하나 또는 그 이상의 약학적으로 허용가능한 담체, 희석제 또는 부형제와 함께 혼합된 제7항 또는 제9항중의 어느 한 항의 화합물을 포함하는 약학적 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930018138A 1992-09-10 1993-09-09 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물 KR940006590A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94335392A 1992-09-10 1992-09-10
US7/943,353 1992-09-10

Publications (1)

Publication Number Publication Date
KR940006590A true KR940006590A (ko) 1994-04-25

Family

ID=25479507

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930018138A KR940006590A (ko) 1992-09-10 1993-09-09 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물

Country Status (20)

Country Link
US (3) US5523314A (ko)
EP (2) EP0915090A1 (ko)
JP (1) JPH06192091A (ko)
KR (1) KR940006590A (ko)
CN (1) CN1091006A (ko)
AU (1) AU676843B2 (ko)
CA (1) CA2105598A1 (ko)
CZ (1) CZ181493A3 (ko)
FI (1) FI933946A (ko)
HU (1) HUT70184A (ko)
IL (1) IL106877A (ko)
MX (1) MX9305444A (ko)
MY (1) MY131443A (ko)
NO (2) NO933198L (ko)
NZ (1) NZ248573A (ko)
PL (1) PL300335A1 (ko)
RU (1) RU2131251C1 (ko)
TW (1) TW274546B (ko)
YU (1) YU59593A (ko)
ZA (1) ZA936492B (ko)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (en) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Modulators of gpr35 for the treatment of metabolic-related disorders
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
ATE238297T1 (de) * 1994-10-20 2003-05-15 Nippon Chemiphar Co Chinolinderivat
US5563277A (en) * 1994-12-21 1996-10-08 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
US5849711A (en) * 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
US5783434A (en) * 1995-06-06 1998-07-21 Tung; Jay S. Cathepsin and methods and compositions for inhibition thereof
CA2221684A1 (en) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Novel cathepsin and methods and compositions for inhibition thereof
JPH09176162A (ja) * 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
BR9710467A (pt) * 1996-07-11 1999-08-17 Warner Lambert Co M-todo para tratamento e preven-Æo de distÚrbios neurodegenerativos atrav-s de administra-Æo de uma tiazolidinona
US6005142A (en) * 1996-09-03 1999-12-21 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives
US6063799A (en) * 1996-09-03 2000-05-16 Eli Lilly And Company Alternate crystal form of Tazofelone
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
EP1006794B1 (en) 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
AU7639598A (en) 1997-05-29 1998-12-30 H. Lundbeck A/S Treatment of schizophrenia and psychosis
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
CA2327444A1 (en) 1998-04-29 1999-11-04 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
AU6330999A (en) * 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
AU6330799A (en) 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders
WO2000024392A1 (fr) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited Inhibiteur de la formation de beta-amyloide
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6127394A (en) * 1999-03-08 2000-10-03 The University Of Mississippi 1,2-Dithiolane derivatives
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
MXPA01009863A (es) * 1999-06-10 2002-05-06 Warner Lambert Co Derivados de rodanina y su uso en la inhibicion y formacion de imagenes amiloides.
BR0011441A (pt) * 1999-06-10 2002-07-16 Warner Lambert Co Derivados de rodanina para uso em um método de inibição da agregação da proteìna amilóide e formação de imagens de depósitos amilóides
WO2001002394A1 (en) * 1999-07-01 2001-01-11 Geron Corporation Substituted indole compounds and their use for the treatment of cancer
ES2248107T3 (es) 1999-08-31 2006-03-16 Incyte San Diego Incorporated Benciliden-tiazolidindionas y analogos y su utilizacion en el tratamiento de la diabetes.
EP1593677A3 (en) * 1999-08-31 2006-01-04 Incyte San Diego Incorporated Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
US6706766B2 (en) * 1999-12-13 2004-03-16 President And Fellows Of Harvard College Small molecules used to increase cell death
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
ATE310733T1 (de) * 2000-04-21 2005-12-15 Pfizer Prod Inc Thyroid-rezeptorliganden
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
AU2001255646A1 (en) * 2000-05-04 2001-11-12 Warner Lambert Company Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
GB0021421D0 (en) * 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
AU2002252227A1 (en) 2001-03-07 2002-09-24 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
WO2002072543A2 (en) * 2001-03-08 2002-09-19 Maxia Pharmaceuticals, Inc. Rxr activating molecules
CA2340824A1 (en) * 2001-03-14 2002-09-14 Ibm Canada Limited-Ibm Canada Limitee Method and system for application behavior analysis
JP2005500379A (ja) * 2001-08-17 2005-01-06 インサイト サンディエゴ インコーポレーテッド 異脂肪血症および高コレステロール血症を治療するオキシム誘導体
AU2002352706A1 (en) * 2001-11-15 2003-06-10 Maxia Pharmaceuticals, Inc. N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
AU2003255528B2 (en) * 2002-07-10 2009-07-16 Merck Serono Sa Azolidinone-vinyl fused-benzene derivatives
US7005523B2 (en) * 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
EP1597255A1 (en) * 2002-11-13 2005-11-23 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
KR20050085115A (ko) 2002-11-22 2005-08-29 스미스클라인 비참 코포레이션 신규 화합물
US20050014767A1 (en) * 2003-01-29 2005-01-20 Magnus Pfahl Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
JP4887139B2 (ja) 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
KR20060036896A (ko) * 2003-04-18 2006-05-02 인사이트 산 디에고 인코포레이티드 대사 장애, 암 및 다른 질병의 치료를 위한 치환된이소크로만 화합물
WO2005007123A2 (en) * 2003-07-18 2005-01-27 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
RU2006107553A (ru) 2003-08-13 2007-09-20 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 4-пиримидона и их применение в качестве ингибиторов пептидилпептидаз
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
NZ549716A (en) 2004-03-15 2010-04-30 Takeda Pharmaceutical Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
DE102005022182A1 (de) * 2005-05-09 2006-11-16 Combinature Biopharm Ag Modulatoren der PDZ-Domäne
PE20070083A1 (es) * 2005-06-08 2007-01-27 Smithkline Beecham Corp (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
NZ566799A (en) 2005-09-14 2011-04-29 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
KR100814109B1 (ko) * 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
US8198466B2 (en) 2006-02-03 2012-06-12 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
DE112007001030T5 (de) 2006-04-28 2009-02-26 Kagoshima University Amyloid-ß-Fibrillogenese-inhibierendes Peptid
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
PT2650378E (pt) 2007-07-31 2016-01-14 Accera Inc Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida
EP2217573A4 (en) * 2007-11-01 2011-08-31 Uab Research Foundation TREATMENT AND PREVENTION OF VIRUS INFECTIONS
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
WO2010019550A2 (en) * 2008-08-12 2010-02-18 Shiraz Pharmaceuticals, Inc. Method of identifying disease risk factors
WO2010114636A1 (en) * 2009-04-03 2010-10-07 Mount Sinai School Of Medicine Of New York University Compositions for treatment of alzheimer's disease
ES2555224T3 (es) * 2009-12-23 2015-12-29 Jasco Pharmaceuticals Llc Inhibidores de aminopirimidina cinasa
JP5733716B2 (ja) * 2009-12-25 2015-06-10 キヤノン株式会社 中枢神経系組織標識用組成物、中枢神経系組織の標識方法、及び中枢神経系組織標識用組成物を用いたスクリーニング方法
CN102558088A (zh) * 2010-12-31 2012-07-11 中国科学院上海药物研究所 联苯亚甲基-2-硫代-4-噻唑酮类化合物及其制备方法和用途
KR20180050420A (ko) 2011-01-10 2018-05-14 진판델 파마슈티컬스 인코포레이티드 알츠하이머 병 치료를 위한 방법 및 약품
JP6014816B2 (ja) 2011-05-10 2016-10-26 国立大学法人神戸大学 Ｒａｓ機能阻害作用を有するチオキソチアゾリジン誘導体
WO2013183718A1 (ja) * 2012-06-06 2013-12-12 国立大学法人京都大学 スクリーニング方法、タンパク質の不安定性及び／又は安定性を誘導する物質、及び、タンパク質の活性評価
CA2890086C (en) 2012-11-05 2022-05-31 Commissariat A L'energie Atomique Et Aux Energies Alternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist preferably a thiazolid nedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
CN104557767B (zh) * 2015-01-14 2016-06-29 成都中医药大学 罗丹宁手性环己烷螺环化合物及其制备方法与用途
CN106008494B (zh) * 2016-05-31 2019-08-27 广东工业大学 一种含4-氧代-2-硫代噻唑烷基衍生物及其制备方法与应用
CN114945569A (zh) * 2019-12-26 2022-08-26 延世大学校产学协力团 吡咯烷衍生物，以及包含其的用于预防或治疗β-淀粉样蛋白或Tau蛋白相关疾病的药物组合物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1038050B (de) * 1955-11-17 1958-09-04 Farmaceutici Italia S A Soc Verfahren zur Herstellung von 5-(3', 4'-Dioxybenzyliden)-Derivaten heterocyclischer Verbindungen
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
AU6610081A (en) * 1980-01-24 1981-07-30 Senju Pharmaceutical Co., Ltd. Thiazolidine derivatives
JPS5728074A (en) * 1980-07-28 1982-02-15 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation, and inhibitor for aldose reducing enzyme consisting essentially of it
JPS5740478A (en) * 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
US4617312A (en) * 1983-01-17 1986-10-14 Pfizer Inc. Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones
US4552891A (en) * 1983-09-13 1985-11-12 Eli Lilly And Company Benzothiophene derivatives
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
JPS6212776A (ja) * 1985-07-10 1987-01-21 Taiho Yakuhin Kogyo Kk ロ−ダニン誘導体
PT83152B (pt) * 1985-08-09 1989-03-30 Lilly Co Eli Processo para a preparacao de compostos di-t-butilfenoicos
US5356917A (en) * 1985-08-09 1994-10-18 Eli Lilly And Company Aryl-substituted rhodanine derivatives
CA1325222C (en) * 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
KR870006897A (ko) * 1986-01-07 1987-08-13 모리오까 시게오 헤테로시클릭 화합물, 그의 제조 방법 및 이를 함유하는 제약 조성물
EP0304493B1 (en) * 1987-03-11 1992-09-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene derivatives
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
IE940525L (en) * 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
US5208250A (en) * 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
US4863923A (en) * 1988-07-01 1989-09-05 Eli Lilly And Company Method of inhibiting superoxide release
ES2088965T3 (es) * 1989-04-07 1996-10-01 Lilly Co Eli Derivados de rodanina aril-sustituidos.
JPH02300119A (ja) * 1989-05-11 1990-12-12 Kanegafuchi Chem Ind Co Ltd 過酸化脂質生成抑制剤
US5116855A (en) * 1989-05-19 1992-05-26 Nisshin Flour Milling Co., Ltd. Rhodanine derivatives and pharmaceutical compositions
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US4997948A (en) * 1989-10-27 1991-03-05 American Home Products 5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
IL96654A (en) * 1989-12-21 1995-06-29 Lilly Co Eli Sutral derivatives containing hydroxybenzyl and sulfur-converted, and pharmaceutical preparations containing them
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
DE4027038A1 (de) * 1990-08-27 1992-03-05 Wella Ag 3-amino-5-benzyliden-2-thioxo-thiazolidin-4- one, verfahren zu deren herstellung und diese enthaltendes kosmetisches mittel
US5158966A (en) * 1991-02-22 1992-10-27 The University Of Colorado Foundation, Inc. Method of treating type i diabetes
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
US5320770A (en) * 1992-04-27 1994-06-14 Dow Corning Corporation Electrorheological (ER) fluid based on amino acid containing metal polyoxo-salts
AU679675B2 (en) * 1992-05-11 1997-07-10 Bayer Corporation Methods for detecting beta amyloid precursor protein processing enzymes
US5236941A (en) * 1992-06-30 1993-08-17 American Home Products Corporation 5-(2-hydroxy-1-arylethylidene)- and 5-(2-oxo-1-arylethylidene)-2,4-thiazolidinediones and derivatives thereof
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
US5506745A (en) * 1994-08-05 1996-04-09 Xerox Corporation Hollow conformable charge roll

Also Published As

Publication number Publication date
NZ248573A (en) 1996-02-27
ZA936492B (en) 1995-03-02
US5523314A (en) 1996-06-04
IL106877A0 (en) 1993-12-28
FI933946A0 (fi) 1993-09-09
MX9305444A (es) 1994-05-31
IL106877A (en) 1998-03-10
US5716975A (en) 1998-02-10
NO981911L (no) 1994-03-11
MY131443A (en) 2007-08-30
NO933198L (no) 1994-03-11
NO981911D0 (no) 1998-04-28
JPH06192091A (ja) 1994-07-12
CN1091006A (zh) 1994-08-24
PL300335A1 (en) 1994-03-21
NO933198D0 (no) 1993-09-08
AU676843B2 (en) 1997-03-27
EP0915090A1 (en) 1999-05-12
EP0587377A2 (en) 1994-03-16
YU59593A (sh) 1997-01-08
HUT70184A (en) 1995-09-28
EP0587377A3 (en) 1994-09-21
FI933946A (fi) 1994-03-11
RU2131251C1 (ru) 1999-06-10
TW274546B (ko) 1996-04-21
CA2105598A1 (en) 1994-03-11
AU4621893A (en) 1994-03-17
CZ181493A3 (en) 1994-03-16
HU9302551D0 (en) 1993-11-29
US5661168A (en) 1997-08-26

Similar Documents

Publication Publication Date Title
KR940006590A (ko) 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물
KR950702982A (ko) 치환된 티아졸리딘디온 유도체(Substituted Thiazolidinedione Derivatives)
KR930701434A (ko) 옥사졸리딘 디온 유도체
KR930702287A (ko) 신규화합물
KR940019699A (ko) 옥사졸리딘디온 유도체, 그의 제조방법 및 용도
KR890002155A (ko) 저혈당제로서의 푸린의 피페라지닐 유도체 및 이의 제조방법
ATE50256T1 (de) Hypoglycemische thiazolidinedione.
DK200001556A (da) Substituerede thiazolidindionderivater
AR016817A1 (es) Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
ES2202322T3 (es) Uso de tiazolidinadionas para el tratamiento de la ateroesclerosis y trastornos de la alimentacion.
KR880009928A (ko) N-헤테로시클릭-n(4-피페리딜) 아미드와 이러한 화합물들을 사용하는 방법 및 제약학적 조성물
HUP0203431A2 (hu) Új heterociklusos vegyületek és sóik, és ezeket tartalmazó gyógyszerkészítmények, valamint felhasználásuk
SE8804628D0 (sv) New compounds
KR870007160A (ko) 신규의 디하이드로벤조푸란-및 크로만-카복스아미드 유도체, 그것의 제조 방법 및 신경이완제로서의 사용법
RU2004122427A (ru) Пирролидин-2-оны в качестве ингибиторов фактора ха
KR940702491A (ko) 옥사졸리돈 유도체
HUP0003260A2 (hu) Gyógyszerkészítmény diabetes kezelésére rosziglitazonnal és inzulinnal
YU47338B (sh) Novo jedinjenje 4-fluoro-2-// (4-metoksi-2-piridinil)metil-/sulfinil/- 1h-benzimidazol i postupak za njegovo dobijanje
RU96123713A (ru) Тиадиазолы и их применение в качестве противопикорнавирусного средства
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
KR880011154A (ko) 벤즈옥사진 유도체 및 이의 제조방법
KR930002314A (ko) 아릴알킬아민 유도체
KR900014397A (ko) 티에노-트리아졸로-디아제핀 술포닐 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR910016734A (ko) 광학활성 알킬렌디옥시벤젠 유도체 및 치료에의 용도
KR880004810A (ko) 소화성 궤양 치료제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application